Cidara Therapeutics (CDTX) Stock Overview
Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CDTX Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cidara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$90.50 |
| 52 Week High | US$90.85 |
| 52 Week Low | US$10.14 |
| Beta | 1.29 |
| 1 Month Change | 38.39% |
| 3 Month Change | 84.57% |
| 1 Year Change | 741.81% |
| 3 Year Change | 722.53% |
| 5 Year Change | 48.84% |
| Change since IPO | -71.72% |
Recent News & Updates
Recent updates
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
Feb 11Cidara Therapeutics: The underestimated potential of CD388
CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Shareholder Returns
| CDTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.9% | -0.7% | -1.0% |
| 1Y | 741.8% | -6.3% | 16.4% |
Return vs Industry: CDTX exceeded the US Biotechs industry which returned -6.3% over the past year.
Return vs Market: CDTX exceeded the US Market which returned 16.4% over the past year.
Price Volatility
| CDTX volatility | |
|---|---|
| CDTX Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDTX's weekly volatility has decreased from 19% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 38 | Jeff Stein | www.cidara.com |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
Cidara Therapeutics, Inc. Fundamentals Summary
| CDTX fundamental statistics | |
|---|---|
| Market cap | US$2.29b |
| Earnings (TTM) | -US$117.10m |
| Revenue (TTM) | n/a |
Is CDTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$108.72m |
| Gross Profit | -US$108.72m |
| Other Expenses | US$8.38m |
| Earnings | -US$117.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CDTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/29 17:22 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cidara Therapeutics, Inc. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Chiang | BTIG |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Eric Schmidt | Cantor Fitzgerald & Co. |